Truist analyst Srikripa Devarakonda raised the firm’s price target on Cytokinetics (CYTK) to $106 from $92 and keeps a Buy rating on the shares. Positive data from ACACIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, support a broader profile for aficamten across the full spectrum of HCM, the analyst tells investors. The firm has updated its model to reflect $5.2B in peak sales in HCM, up from $4.8B forecast previously.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics report ‘arguably a best-case scenario’ for Edgewise, says Stifel
- Cytokinetics Phase 3 data bodes well for Edgewise, says Raymond James
- This Is Why Cytokinetics Stock (CYTK) Soared Today
- Cytokinetics reports ACACIA-HCM trial met both primary endpoints
- CYTK Earnings this Week: How Will it Perform?